● Recruiting

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Condition: Pancreatic Cancer, Adult · Sponsor: Tianjin Medical University Cancer Institute and Hospital

PhasePhase 3

Planned participants106

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer

This description comes directly from the study's public registry record.

Talk to the study team

Jihui Hao, M.D. · 022-23524155 · ec_tjcih@126.com

Song Gao, M.D. · foxgao2004@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07436741